Jpmorgan Chase & CO Durect Corp Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.38 - $0.64 $1.04 Million - $1.75 Million	-2,737,010 Reduced 99.96%	1,094 $1,000
Q1 2022 May 11, 2022	SELL	$0.55 - $0.98 $52,448 - $93,453	-95,361 Reduced 3.37%	2,738,104 $1.84 Million
Q4 2021 Feb 10, 2022	SELL	$0.9 - $1.31 $85,191 - $124,000	-94,657 Reduced 3.23%	2,833,465 $2.79 Million
Q3 2021 Nov 12, 2021	BUY	$1.21 - $1.61 $3.54 Million - $4.71 Million	2,928,122 New	2,928,122 $3.75 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $180M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.